Retatrutide – Innovative triple GLP-1/GIP/GCGR agonist: a research overview

Peptology · 2026-06-04

🧬 Retatrutide – a triple GLP-1/GIP/glucagon receptor agonist in research

Retatrutide is an experimental peptide that is attracting increasing attention in metabolic research. It belongs to the newer generation of incretin-based multi-agonists and is being studied in clinical trials for its effects on body weight, appetite regulation and metabolic markers.

How does Retatrutide work?

Retatrutide is a tri-agonist – it simultaneously activates three key receptors:

• GLP-1 (glucagon-like peptide-1) – suppresses appetite, slows gastric emptying and supports insulin sensitivity;

• GIP (glucose-dependent insulinotropic polypeptide) – improves glucose control;

• Glucagon receptor – increases energy expenditure by stimulating metabolism and lipolysis.

In studies, the combined action of these three pathways has been associated with:

• Reduction of excess body weight;

• Improvement of blood glucose and insulin sensitivity;

• Reduction of fat mass and inflammatory processes.

What do the studies show?

🔬 Phase 2 results:
In the 48-week phase 2 trial, the highest-dose group showed a mean weight reduction of 24.2% versus 2.1% with placebo. The trial did not compare retatrutide directly with semaglutide or tirzepatide.

💡 Targeted action:
Retatrutide acts on the brain's hunger centres and also directly on metabolic pathways, reducing fat accumulation and improving energy utilisation.

🛡️ Adverse events in trials:
The most common adverse events reported in the trials were gastrointestinal (nausea, diarrhoea, vomiting) – similar to those observed with other GLP-1 agonists.

---

Conclusion

Retatrutide is an experimental triple agonist of the GLP-1, GIP and glucagon receptors. Phase 2 data show a substantial weight reduction and changes in metabolic markers; phase 3 trials are ongoing. It is not an approved medicine.

At Peptology, Retatrutide is available as a research peptide for laboratory use only, with an HPLC/MS report for every batch.

---

🤔 How does Retatrutide differ from Semaglutide?

Semaglutide is a GLP-1 receptor mono-agonist, while Retatrutide also activates the GIP and glucagon receptors. Its phase 2 trial reported a larger mean weight reduction (24.2% at 48 weeks) than STEP 1 with semaglutide (14.9% at 68 weeks), but these are separate trials with different populations and durations, not a head-to-head comparison.